Colorectal cancer

Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024
SAN, CDTX, AACR, Therapy, Abstract, Patient, Drug, San Diego Convention Center, DFC, Colorectal cancer, CCR5

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting three abstracts and one late-breaking abstract during the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.

Key Points: 
  • SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the company will be presenting three abstracts and one late-breaking abstract during the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.
  • Presentation details are summarized below:
    Abstract Title: CCR5-001, a novel Drug Fc-Conjugate (DFC) targeting CCR5, demonstrates potent efficacy in a colorectal cancer mouse model
    Presenters: Elizabeth Abelovski and Nicholas Dedeic, Ph.D.

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Retrieved on: 
Tuesday, March 5, 2024
Senior, Biotechnology, NPV, PMA, Messenger, FDA, Partnership, Marketing, PPV, Food, CRC, AA, Biomarker, Science, Quest Diagnostics, THA, Patient, Clinical trial, Survival, DRS, Colorectal cancer, Gene expression, Medical imaging

In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.

Key Points: 
  • In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.
  • The Company currently commercializes its first-generation test in Europe and in select international territories through its flagship product ColoAlert® via partnerships with third-party laboratories.
  • “Detecting AA lesions allows for early intervention and significantly increases the chance of successful treatment and survival.
  • The study’s primary objectives include calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) in average-risk subjects for CRC and AA.

3 Tips to Nourish Your Body for National Nutrition Month in March

Retrieved on: 
Monday, March 4, 2024
Nut, Diet, Chopped, Mineral, Vitamin, Skin, Food, Grain boundary strengthening, Risk, Seed, Health, Vegetable, Type 2 diabetes, Yogurt, Digestion, Lettuce, Taste, Colorectal cancer, Dietary supplement

Oakville, Ontario, March 04, 2024 (GLOBE NEWSWIRE) -- In Canada, March marks National Nutrition Month, a time to reevaluate our understanding of food and its impact on our health.

Key Points: 
  • Oakville, Ontario, March 04, 2024 (GLOBE NEWSWIRE) -- In Canada, March marks National Nutrition Month, a time to reevaluate our understanding of food and its impact on our health.
  • We know that the amount of information (and disinformation) about nutrition can be overwhelming.
  • Here are 3 tips to nourish your body, enhance your daily eating and support your overall well-being:
    Not all calories are created equal.
  • So, in celebration of National Nutrition Month in March, why not give these 3 strategies a try.

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 1, 2024
PD, Research, SRC, Melanoma, FDA, Research and development, Immunotherapy, Food, Binimetinib, AACR, Benchmarking, Cmax, RAS, Safety, RAF, Neoplasm, Pharmacokinetics, PDAC, Administration, Paclitaxel, Patient, Clinical trial, Lung cancer, Half-life, Circulating tumor DNA, MAPK, Pancreatic cancer, Cancer, Colorectal cancer, DNA, Pharmaceutical industry

“We look forward to sharing topline data from the Phase 1 portion of the Phase 1/2a trial of IMM-1-104 this month.

Key Points: 
  • “We look forward to sharing topline data from the Phase 1 portion of the Phase 1/2a trial of IMM-1-104 this month.
  • Presented preclinical data demonstrating encouraging anti-tumor activity for IMM-1-104 and IMM-6-415: In October 2023, Immuneering presented preclinical data at AACR-NCI-EORTC.
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $11.9 million compared with $9.9 million for the fourth quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $4.4 million compared with $4.1 million for the same period of 2022.

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, February 28, 2024
Active, VSIG4, MSS, National Cancer Institute, Society, Sensei, Lung cancer, Patient, Immunotherapy, Trial of the century, Head, Neoplasm, VISTA, SITC, MBA, Annual general meeting, Therapy, Histology, Biology, NSCLC, ESMO, Kinetics, CRC, PD-1, Conference, Safety, Cemiplimab, Pharmacokinetics, CRADA, CD39, IND, Colorectal cancer, Translation, NCI, Aes, Part-time, FDA, Research and development, Administration, KOL, Cancer, Pharmaceutical industry

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2023, and provided corporate updates.

Key Points: 
  • “2023 saw the entry of our differentiated anti-VISTA antibody, SNS-101, into clinical development,” said John Celebi, President and Chief Executive Officer.
  • Recent updates include:
    A total of 33 patients have been treated with SNS-101 +/- Libtayo in the dose escalation phase of this study.
  • On October 23, 2023 , Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Wednesday, February 28, 2024
NSCLC, Research, Gene, GSK, TIL, SITC, Growth, AP-1 transcription factor, Cell, International Society, NR4A3, Annual general meeting, Lung cancer, Society, Triple-negative breast cancer, GAAP, Biomarker, Phenotype, TNBC, Patient, Organization, Survival, TCR, Lyell, GSK plc, ISSCR, G&A, Literature, Workforce, IND, Corporation, Colorectal cancer, Vaccine

The study includes patients with relapsed or refractory triple-negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC).

Key Points: 
  • The study includes patients with relapsed or refractory triple-negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC).
  • The increase in fourth quarter 2023 non-GAAP R&D expenses was driven by an increase in research and laboratory costs primarily associated with clinical trials.
  • The decrease in both fourth quarter 2023 and annual 2023 G&A expenses were both primarily driven by decreases in non-cash stock-based compensation.
  • The decrease in 2023 non-GAAP G&A expenses was driven by a decrease in legal and corporate expenses.

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Retrieved on: 
Tuesday, February 27, 2024
VEGA, ALTAIR, Division, Recurrence, Doctor of Philosophy, MYGN, Cancer, Myriad Genetics, WGS, Neoplasm, Medicine, Genetic testing, Patient, MRD, Genetics, Head, Colorectal cancer, Research, DNA

Two of the three cohorts, including approximately 1,200 patients across more than 20 cancer types, will undergo MRD monitoring via Precise MRD.

Key Points: 
  • Two of the three cohorts, including approximately 1,200 patients across more than 20 cancer types, will undergo MRD monitoring via Precise MRD.
  • The goal of SCRUM-MONSTAR-SCREEN-3 is to generate high-quality, prospective, clinical evidence showing MRD testing can be broadly applied across cancer types and to patients with different disease severity or staging.
  • “First generation MRD tests have made remarkable progress monitoring disease recurrence and progression in cancer types with high tumor or variant burden.
  • “We’ve designed Precise MRD to be highly sensitive for application across all cancer types and look forward to this study demonstrating its utility in cancer care.”

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Retrieved on: 
Tuesday, February 27, 2024
Head, Neoplasm, DCR, Cetuximab, ESMO, Aes, Drug resistance, Escape Room, Immunotherapy, SCCHN, University, Nausea, Squamous-cell carcinoma, Tumor microenvironment, Patient, Congress, HPV, Plasma, Colorectal cancer, Pharmaceutical industry

REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) --   Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced clinical results from its Phase 1/2 dose escalation study of NT219 in combination with cetuximab in the treatment of patients with recurrent/metastatic head and neck cancer (R/M SCCHN).

Key Points: 
  • The Phase 1/2 dose escalation study (NCT04474470) evaluated NT219 as a monotherapy in various indications and in combination with cetuximab in the treatment of R/M SCCHN and colorectal cancer.
  • As of cut-off date of January 25, 2024:
    Seventeen patients with R/M SCCHN were enrolled in the combination arm of NT219 + cetuximab.
  • The median number of prior lines of therapy was 2 and 94% of the patients received prior immunotherapy.
  • “We were encouraged to see anti-tumor activity in HPV negative patients,” said Dr. Michael Schickler, Purple Biotech’s Head of Clinical and Regulatory Affairs.

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Retrieved on: 
Tuesday, February 27, 2024
Gynaecology, Culture, Blood, Urology, Gastroenterology, CRC, FIT, Internal medicine, The German, Practitioner, Congress, Colorectal cancer, DNA, Cancer, Pharmaceutical industry

This data underscores the significant impact gynecologists have in the early detection and prevention efforts against CRC.

Key Points: 
  • This data underscores the significant impact gynecologists have in the early detection and prevention efforts against CRC.
  • The Gynecology Congress is a premier event dedicated to gynecological health, offering Mainz Biomed an invaluable opportunity to connect with these vital healthcare providers.
  • This effort is aimed at increasing brand awareness and establishing ColoAlert® as a key component in medical practices for CRC screening.
  • In the coming months, Mainz Biomed will continue to actively participate in medical conferences that cater to its key demographic.

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

Retrieved on: 
Monday, February 26, 2024
NSCLC, Acquisition, Research, Neoplasm, Investment, Melanoma, Conference, RAS, Lung cancer, Safety, Sanofi, GAAP, PDAC, Patient, Acceleration, Clinical trial, Congress, Trial of the century, Colorectal cancer, Pharmaceutical industry

“2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors.

Key Points: 
  • “2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors.
  • Revenue: Total revenue was $0.7 million for the quarter ended December 31, 2023, compared to $15.3 million for the quarter ended December 31, 2022.
  • Net loss for the year ended December 31, 2023, included $26.9 million of operating expenses related to the wind-down of EQRx.
  • Revolution Medicines will host a webcast this afternoon, February 26, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).